Clinical trials: Diabetes Type I
Hypoglycemia, Diabetes Mellitus, Type 1
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for hypoglycemia rescue of adult patients with type 1…
- Trial name
- NCT02656069
- Testing
- G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
- Where
- 7 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Xeris Pharmaceuticals
Type 1 Diabetes Mellitus
Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the dose-response pattern of the glucose consumption (GIR-AUC0-end) of 3 different single doses of Afrezza inhaled Technosphere insulin and of 3 single doses of subcutaneous (SC) insulin lispro in a…
- Trial name
- NCT02470637
- Testing
- SAR439065, Insulin lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection.
- Trial name
- NCT01997411
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Type I Diabetes
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
This is an open label, randomized, parallel group comparison of the immunogenicity safety of Wockhardt's human insulin and isophane insulin compared with the Novo Nordisk's yeast based human insulin products (marketed in USA) in…
- Trial name
- NCT01308437
- Testing
- Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
- Where
- 25 sites in United States, India
- Volunteers
- 134 people
- Sponsor
- Wockhardt
Type 1 Diabetes Mellitus
Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus
Alpha-1 Antitrypsin (AAT), trade name (Glassia ®), is being explored in this phase I/II trial as a potential disease modifying agent in Type 1 Diabetes Mellitus (T1DM) based on its anti-inflammatory properties.
- Trial name
- NCT01304537
- Testing
- Alpha-1 Antitrypsin 40mg (AAT, Glassia®), Alpha-1 Antitrypsin 60mg (AAT, Glassia®), Alpha-1 Antitrypsin 80mg (AAT, Glassia®)
- Where
- 2 sites in Israel
- Volunteers
- 24 people
- Sponsor
- Kamada, Ltd.
Type 1 Diabetes Mellitus
Prepivotal Omnipod Horizon™ Automated Glucose Control System
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 14-day hybrid closed-loop phase conducted in both a hotel/rental house setting…
- Trial name
- NCT04176731
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Insulet Corporation
Non-Insulin-Dependent Diabetes Mellitus
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.
- Trial name
- NCT00359112
- Testing
- metformin, sulphonylurea, Avandamet
- Where
- 142 sites in Belgium, France and 9 more
- Volunteers
- 544 people
- Sponsor
- GlaxoSmithKline
Gastroparesis
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
This study is a randomized, double-blind, placebo controlled trial designed to confirm the symptomatic effects of camicinal treatment vs. placebo, on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis.
- Trial name
- NCT02210000
- Testing
- Camicinal
- Where
- 34 sites in United States
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Diabetes
This observational study is conducted in North America. The aim of this observational study is to evaluate the incidence of adverse events while using Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT00706017)
- Testing
- insulin detemir
- Where
- Mexico
- Volunteers
- 2,282 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470
The purpose of this study is to investigate safety, tolerability, pharmacokinetics (PK) ad pharmacodynamics (PD) of HM12470 after single injection in T1DM and T2DM patients.
- Trial name
- NCT02302443
- Testing
- HM12470, Active comparator
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor
The purpose of the study is to assess the performance of a new subcutaneous glucose sensor over a seven-day sensor life when used with currently marketed Medtronic Diabetes devices.
- Trial name
- NCT01112696
- Testing
- Sensor wear
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Medtronic MiniMed, Inc.
T2DM (Type 2 Diabetes Mellitus)
Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study. The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a…
- Trial name
- NCT07511010
- Testing
- Chiglitazar/Metformin extended-release tablets under fasting conditions, Chiglitazar/Metformin extended-release tablets after a high-fat meal, multiple-dose of Chiglitazar/Metformin extended-release tablets
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Diabetes Mellitus Type 1
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.
- Trial name
- NCT01334151
- Testing
- Insulin LISPRO, recombinant human insulin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Biodel
Type I Diabetes Mellitus
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus
The purpose of this study is: to assess clinical efficacy of Subetta in the combined treatment of type I diabetes mellitus; to assess safety of Subetta in the combined treatment of type I diabetes mellitus.
- Trial name
- NCT01868594
- Testing
- Subetta
- Where
- 15 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Materia Medica Holding
Health Adult Subjects, Obesity & Overweight
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
- Trial name
- NCT07675590
- Testing
- TIX100
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- TIXiMED, Inc.
Diabetes Mellitus, Type 1
Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After Eating
This study is to determine the effect of intra-dermal (ID) administration of regular and of rapid-acting insulin, before eating, on blood glucose levels for several hours after a standard meal (a mixed, liquid meal).
- Trial name
- NCT00553488
- Testing
- Regular insulin (Humulin), Insulin lispro (Humalog)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Diabetes Mellitus, Type 1
Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature
A prospective, multicenter evaluation of performance and safety of the Eversense Gemini System with flash glucose measurement feature.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT07386340
- Testing
- Continuous Glucose Monitoring System
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Senseonics, Inc.
Type 1 Diabetes Mellitus
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with type 1 diabetes mellitus.
- Trial name
- NCT05272059
- Testing
- MHS552
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 1
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy
The aim of the project is to document the international routine practice in sensor usage in patients treated with sensor-augmented pump therapy and to assess which variables (e.g.
- Trial name
- NCT00790088
- Where
- 26 sites in Austria, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.
- Trial name
- NCT06704672
- Testing
- Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
- Where
- 20 sites in Poland, Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.